CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Vitiligo
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Vitiligo Pigmentation Disorder Treatment Market by Type
4.2.4.1 Segmental Market size and forecast, by region
4.2.4.2 Non-segmental Market size and forecast, by region
4.3 Melasma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Corticosteroids
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Calcineurin inhibitor
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: PIGMENTATION DISORDER TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.2.1 North America Vitiligo Pigmentation Disorder Treatment Market by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.2.1 Europe Vitiligo Pigmentation Disorder Treatment Market by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.2.1 Asia-Pacific Vitiligo Pigmentation Disorder Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.2.1 LAMEA Vitiligo Pigmentation Disorder Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Arcutis Biotherapeutics
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Astellas Pharma Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Incyte Corporation
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Dermavant Science Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Viatirs Inc. (Mylan N.V.)
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Galderma SA
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Obagi Cosmeceuticals LLC
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Dr. Reddy’s Laboratories Limited
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Glenmark Pharmaceuticals Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
TABLE 1. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 2. PIGMENTATION DISORDER TREATMENT MARKET, FOR VITILIGO, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PIGMENTATION DISORDER TREATMENT MARKET FOR VITILIGO, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. GLOBAL VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 5. PIGMENTATION DISORDER TREATMENT MARKET, FOR SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
TABLE 6. PIGMENTATION DISORDER TREATMENT MARKET, FOR NON-SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
TABLE 7. PIGMENTATION DISORDER TREATMENT MARKET, FOR MELASMA, BY REGION, 2021-2031 ($MILLION)
TABLE 8. PIGMENTATION DISORDER TREATMENT MARKET FOR MELASMA, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 9. PIGMENTATION DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. PIGMENTATION DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 11. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 12. PIGMENTATION DISORDER TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. PIGMENTATION DISORDER TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. PIGMENTATION DISORDER TREATMENT MARKET, FOR CALCINEURIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
TABLE 15. PIGMENTATION DISORDER TREATMENT MARKET FOR CALCINEURIN INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. PIGMENTATION DISORDER TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 17. PIGMENTATION DISORDER TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 18. GLOBAL PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 19. PIGMENTATION DISORDER TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 20. PIGMENTATION DISORDER TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. PIGMENTATION DISORDER TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 22. PIGMENTATION DISORDER TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. PIGMENTATION DISORDER TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 24. PIGMENTATION DISORDER TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 25. PIGMENTATION DISORDER TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 31. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 32. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 33. U.S. PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 34. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 35. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 36. CANADA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 38. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 39. MEXICO PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 41. EUROPE VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 42. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 43. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 45. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 46. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 47. GERMANY PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 48. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 49. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 50. FRANCE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 51. UK PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 52. UK PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 53. UK PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 54. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 55. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 56. ITALY PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 57. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 58. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 59. SPAIN PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 60. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 68. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 69. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 70. JAPAN PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 72. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 73. CHINA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 74. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 75. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 76. INDIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 77. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 80. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 83. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 86. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 87. LAMEA VITILIGO PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 88. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 89. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 91. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 92. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 93. BRAZIL PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 94. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 97. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 100. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 103.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
TABLE 104.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
TABLE 105.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
TABLE 106.ARCUTIS BIOTHERAPEUTICS: NET SALES,
TABLE 107.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
TABLE 108.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
TABLE 109.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
TABLE 110.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
TABLE 111.ASTELLAS PHARMA INC.: NET SALES,
TABLE 112.ASTELLAS PHARMA INC.: KEY STRATERGIES
TABLE 113.BAUSCH HEALTH COMPANIES INC: COMPANY SNAPSHOT
TABLE 114.BAUSCH HEALTH COMPANIES INC: OPERATING SEGMENTS
TABLE 115.BAUSCH HEALTH COMPANIES INC: PRODUCT PORTFOLIO
TABLE 116.BAUSCH HEALTH COMPANIES INC: NET SALES,
TABLE 117.BAUSCH HEALTH COMPANIES INC: KEY STRATERGIES
TABLE 118.INCYTE CORPORATION: COMPANY SNAPSHOT
TABLE 119.INCYTE CORPORATION: OPERATING SEGMENTS
TABLE 120.INCYTE CORPORATION: PRODUCT PORTFOLIO
TABLE 121.INCYTE CORPORATION: NET SALES,
TABLE 122.INCYTE CORPORATION: KEY STRATERGIES
TABLE 123.DERMAVANT SCIENCE INC.: COMPANY SNAPSHOT
TABLE 124.DERMAVANT SCIENCE INC.: OPERATING SEGMENTS
TABLE 125.DERMAVANT SCIENCE INC.: PRODUCT PORTFOLIO
TABLE 126.DERMAVANT SCIENCE INC.: NET SALES,
TABLE 127.DERMAVANT SCIENCE INC.: KEY STRATERGIES
TABLE 128.VIATIRS INC. (MYLAN N.V.): COMPANY SNAPSHOT
TABLE 129.VIATIRS INC. (MYLAN N.V.): OPERATING SEGMENTS
TABLE 130.VIATIRS INC. (MYLAN N.V.): PRODUCT PORTFOLIO
TABLE 131.VIATIRS INC. (MYLAN N.V.): NET SALES,
TABLE 132.VIATIRS INC. (MYLAN N.V.): KEY STRATERGIES
TABLE 133.GALDERMA SA: COMPANY SNAPSHOT
TABLE 134.GALDERMA SA: OPERATING SEGMENTS
TABLE 135.GALDERMA SA: PRODUCT PORTFOLIO
TABLE 136.GALDERMA SA: NET SALES,
TABLE 137.GALDERMA SA: KEY STRATERGIES
TABLE 138.OBAGI COSMECEUTICALS LLC: COMPANY SNAPSHOT
TABLE 139.OBAGI COSMECEUTICALS LLC: OPERATING SEGMENTS
TABLE 140.OBAGI COSMECEUTICALS LLC: PRODUCT PORTFOLIO
TABLE 141.OBAGI COSMECEUTICALS LLC: NET SALES,
TABLE 142.OBAGI COSMECEUTICALS LLC: KEY STRATERGIES
TABLE 143.DR. REDDY'S LABORATORIES LIMITED: COMPANY SNAPSHOT
TABLE 144.DR. REDDY'S LABORATORIES LIMITED: OPERATING SEGMENTS
TABLE 145.DR. REDDY'S LABORATORIES LIMITED: PRODUCT PORTFOLIO
TABLE 146.DR. REDDY'S LABORATORIES LIMITED: NET SALES,
TABLE 147.DR. REDDY'S LABORATORIES LIMITED: KEY STRATERGIES
TABLE 148.GLENMARK PHARMACEUTICALS LTD: COMPANY SNAPSHOT
TABLE 149.GLENMARK PHARMACEUTICALS LTD: OPERATING SEGMENTS
TABLE 150.GLENMARK PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
TABLE 151.GLENMARK PHARMACEUTICALS LTD: NET SALES,
TABLE 152.GLENMARK PHARMACEUTICALS LTD: KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
